|
Forecast
Period
|
2026-2030
|
|
Market
Size (2024)
|
USD
35.76 Billion
|
|
Market
Size (2030)
|
USD
58.51 Billion
|
|
CAGR
(2025-2030)
|
8.51%
|
|
Fastest
Growing Segment
|
Immunoglobulins
|
|
Largest
Market
|
North
America
|
Market Overview
Global Blood Plasma Fractionation Market was valued
at USD 35.76 Billion in 2024 and is expected to reach USD 58.51 Million by 2030
with a CAGR of 8.51% during the forecast period. The Global Blood Plasma
Fractionation Market is primarily driven by the increasing demand for
plasma-derived therapies, which are essential for treating various chronic and
life-threatening conditions such as hemophilia, immunodeficiencies, and
autoimmune disorders. As the global prevalence of these diseases rises, the
need for blood plasma products grows, fueling market expansion. Advancements in
fractionation technologies, enabling more efficient and cost-effective
production processes, contribute to market growth. The growing focus on
healthcare infrastructure in emerging economies and the rising awareness of
plasma donation programs further support market demand. The increasing number
of plasma collection centers and the supportive regulatory frameworks also play
a significant role in the development of the market, ensuring a steady supply
of high-quality plasma products.
Key Market Drivers
Growing Awareness and Investment in Plasma Donation
The increasing awareness of the importance of blood
plasma donation plays a significant role in driving the global blood plasma
fractionation market. Plasma is a renewable resource, but it must be collected
regularly, requiring widespread participation in donation programs.
Governments, non-governmental organizations (NGOs), and healthcare providers
around the world are working to raise awareness about the critical role of
plasma in treating diseases and the life-saving potential of plasma donation. According
to WHO, Globally, 118.5 million blood donations are collected each year, with
40% of these donations coming from high-income countries, which account for
just 16% of the world's population. In low-income countries, up to 54% of blood
transfusions are administered to children under the age of 5, whereas in
high-income countries, the most common recipients are individuals over 60, who
receive up to 76% of all transfusions. Blood donation rates vary significantly
across income levels, with high-income countries averaging 31.5 donations per
1,000 people, upper-middle-income countries at 16.4 donations,
lower-middle-income countries at 6.6 donations, and low-income countries at 5.0
donations per 1,000 people.
In countries like the United States, where plasma
collection centers are in abundance, many efforts are made to encourage regular
plasma donations. These initiatives help to ensure a steady and reliable supply
of plasma for fractionation, thus enabling pharmaceutical companies to meet the
growing demand for plasma-derived products. Increased public awareness and
education about the process, as well as the benefits of plasma donation,
contribute to a larger donor pool. The rise in plasma donor compensation programs
has made donating more attractive, encouraging higher donation rates and
further supporting the growth of the plasma fractionation market.
Investment from both the private and public sectors
has also been critical in the expansion of plasma collection centers and
infrastructure. Increased financial support has allowed for the establishment
of more donation centers, providing greater access to plasma collection and
ensuring a more robust supply chain for fractionation.
Aging Global Population
The aging population is a major driver of the blood
plasma fractionation market. As people live longer, the prevalence of
age-related conditions like hemophilia, immunodeficiencies, and chronic
autoimmune diseases has risen significantly. Older individuals are more likely
to develop conditions that require plasma-derived therapies, such as immune
disorders that can result from the natural decline in immune system function
with age. According to WHO, he global population aged 60 and over is projected to
rise from 1 billion in 2020 to 1.4 billion. By 2050, the number of people aged
60 and above is expected to double, reaching 2.1 billion. The population aged
80 and older is forecasted to triple between 2020 and 2050, reaching 426
million.
For example, immunoglobulin therapies are commonly
used to treat patients with primary immune deficiencies and autoimmune
conditions like rheumatoid arthritis and lupus, which are more common among
older adults. The demand for plasma products like immunoglobulins, clotting
factors, and albumin is therefore expected to grow in parallel with the aging
demographic.
As the aging population increases worldwide,
especially in developed regions such as Europe and North America, healthcare
systems must adapt to meet the rising demand for these life-saving treatments.
This demographic shift creates an ongoing need for the production of
plasma-derived therapies, which in turn drives the market for blood plasma
fractionation.
Expanding Plasma Collection Infrastructure
The expansion of plasma collection infrastructure
is a significant driver of the blood plasma fractionation market. With the
rising demand for plasma-derived therapies, there is a growing need for more
plasma collection centers worldwide. To meet this demand, the number of
dedicated plasma collection centers has increased, especially in regions like
North America, Europe, and Asia.
Plasma collection centers serve as the primary
source of plasma, which is then processed through fractionation to create
life-saving therapies. The establishment of new centers is essential for
maintaining a steady and sufficient supply of plasma, which directly influences
the availability of therapies such as immunoglobulins, clotting factors, and
albumin. Advances in plasma collection techniques have made the process more
efficient, allowing collection centers to handle larger volumes of plasma,
ensuring adequate supply.
The expansion of plasma collection infrastructure
is also supported by improved logistics and transportation systems, ensuring
that plasma can be quickly and safely delivered to fractionation facilities.
The growing number of collection centers, combined with innovations in the
collection process, is a major driver of the market, as it enhances the supply
chain and ensures consistent product availability.
Rising Incidence of Chronic Diseases and Rare
Disorders
The increasing prevalence of chronic diseases and
rare disorders is another important factor driving the blood plasma
fractionation market. Chronic conditions such as hemophilia, autoimmune
diseases, and immunodeficiencies often require ongoing treatment with
plasma-derived therapies. For example, hemophilia A and B patients need regular
infusions of clotting factors derived from blood plasma to manage bleeding
episodes. In the European Union, it is estimated that between 27 and 36 million
people are living with a rare disease. Currently, there are between 6,000 and
8,000 distinct rare diseases, with some affecting only a few patients, while
others can impact as many as 245,000 individuals. Approximately 80% of rare
diseases are of genetic origin, and 70% of these conditions begin during
childhood.
The rise in the global burden of these diseases is
expected to lead to a higher demand for plasma products. Rare genetic
disorders, such as certain types of immunodeficiencies, also require
specialized therapies that are derived from plasma. As the global population
becomes more aware of these disorders and as diagnostic methods improve, early
diagnosis is leading to an increased need for plasma therapies.
In countries with higher healthcare spending,
especially in developed economies, there is a greater emphasis on providing
advanced treatments for chronic diseases, which further drives the demand for
plasma-based therapies. As medical research continues to reveal new
applications for plasma-derived products in treating chronic conditions, the
market for blood plasma fractionation is poised for continued growth.
Increased Healthcare Expenditure and Investment in
Medical Research
Increased healthcare expenditure and investment in
medical research are key drivers in the global blood plasma fractionation
market. Governments and private entities are investing heavily in healthcare
infrastructure and research to better understand and treat diseases that
require plasma-derived therapies. This has led to breakthroughs in medical
science, including more effective treatments for autoimmune diseases,
hemophilia, and other conditions that depend on plasma products.
Higher healthcare spending allows for the
development of cutting-edge medical treatments, the expansion of plasma
collection and fractionation infrastructure, and the continued advancement of
technologies to improve plasma fractionation processes. Research into
optimizing plasma collection and processing techniques has been a significant
focus, improving the cost-effectiveness and scalability of plasma-derived
therapies.
As healthcare systems allocate more resources to
improve patient outcomes, especially for chronic and rare diseases, investment
in plasma-based therapies has surged, driving market growth. These investments
not only increase the availability of plasma-derived products but also
contribute to ongoing innovation within the market, further accelerating its
expansion.
Download Free Sample Report
Key Market Challenges
High Costs of Plasma Fractionation
One of the major challenges in the blood plasma
fractionation market is the high cost of plasma-derived products. Plasma
fractionation is a complex and resource-intensive process, requiring
sophisticated technologies and specialized infrastructure. The costs associated
with collecting, processing, and purifying blood plasma to derive specific
therapeutic proteins such as immunoglobulins, clotting factors, and albumin are
substantial.
These high costs are passed on to patients and
healthcare systems, making these life-saving therapies expensive and less
accessible, especially in lower-income countries. The production of
plasma-based therapies is highly regulated to ensure quality and safety, which
adds additional financial burdens. As demand continues to rise, there is
increasing pressure to reduce costs while maintaining product quality, which is
a delicate balance for the industry.
Plasma Shortages and Supply Chain Constraints
The global demand for blood plasma-derived
therapies is growing, but the supply of plasma is often insufficient to meet
this demand. Plasma collection is highly dependent on voluntary donations, and
there are regional disparities in donation rates. Countries with low donation
rates face challenges in ensuring a steady and sufficient plasma supply, which
impacts the entire supply chain from collection to fractionation.
Logistical challenges, such as transportation of
plasma across long distances, the need for proper storage conditions, and
potential delays in collection, further complicate the supply chain. Shortages
in plasma availability could lead to delays in therapy production and a lack of
access to essential treatments, especially in regions where healthcare systems
are underfunded or less developed.
Technological and Operational Limitations in Plasma
Fractionation
While advancements in plasma fractionation
technologies have improved efficiency and yield, the process is still limited
by technological and operational constraints. Plasma fractionation is a
delicate process that requires high levels of expertise, and any failure in the
fractionation process can result in the loss of valuable plasma and raw
materials. This makes scaling up production challenging, as large-scale
fractionation facilities must maintain consistently high standards of
performance and quality.
The complex nature of plasma fractionation requires
significant investment in advanced technologies and infrastructure. Smaller
companies and organizations in less developed regions may struggle to afford
these investments, leading to disparities in production capabilities across the
globe. Operational challenges, such as the need for specialized equipment,
trained personnel, and quality control systems, add to the difficulties faced
by the industry. These limitations can impact the scalability of plasma-based
products, preventing certain regions from fully tapping into the market
potential.
Key Market Trends
Increasing Demand for Plasma-Derived Therapies
The rising demand for plasma-derived therapies is a
key driver in the blood plasma fractionation market. Plasma-derived therapies,
which include clotting factor concentrates, immunoglobulins, and albumin, are crucial
for treating a wide variety of medical conditions, including bleeding
disorders, immunodeficiencies, and liver diseases. Hemophilia, a genetic
disorder characterized by an inability to clot blood, is one of the main
conditions treated with plasma-derived products like clotting factors. As the
global incidence of these diseases continues to rise, especially among the
aging population, the demand for these life-saving therapies has expanded
dramatically. In September 2024, Grifols, a global
healthcare company, partnered with French telecom giant Orange to establish a
sustainable supply of vital therapeutics for life-threatening diseases in
Egypt. Orange Business, the enterprise division of Orange Group, has
successfully completed the first phase of a new data center and communication
infrastructure in Cairo, aimed at supporting Grifols Egypt for Plasma
Derivatives (GEPD). This collaboration is designed to enhance healthcare
capabilities in the country by ensuring a reliable supply of essential
plasma-derived products.
In addition, advancements in medical treatments and
a growing understanding of chronic conditions such as autoimmune disorders and
immunodeficiencies have resulted in an increased need for immunoglobulins,
which are derived from blood plasma. These therapies play a crucial role in
helping patients manage conditions like rheumatoid arthritis, lupus, and
primary immune deficiencies. The ability of plasma-derived therapies to provide
long-term, life-sustaining treatment for chronic conditions has made them essential
in healthcare systems worldwide, thus propelling the growth of the blood plasma
fractionation market. The expanding use of these therapies has also driven up
the demand for blood plasma collection and fractionation technologies, which
can process large quantities of plasma while ensuring product safety, quality,
and efficacy. As a result, medical research and development efforts continue to
focus on improving the effectiveness and accessibility of plasma-based
treatments, ensuring sustained market growth in this sector.
Advancements in Fractionation Technologies
Technological advancements in plasma fractionation
techniques are a significant driver of the global market. Fractionation is the
process of separating blood plasma into its various components, including
immunoglobulins, clotting factors, albumin, and other proteins, each with
specific medical uses. With the rise in demand for high-quality plasma
products, the need for advanced, efficient, and cost-effective fractionation
methods has become more critical.
Over the years, fractionation technologies have
evolved from older, less efficient methods to highly automated, large-scale
processes that offer greater yields and faster processing times. This has
allowed for the more efficient extraction and purification of proteins from
plasma, thereby meeting the increasing demand. Newer methods have reduced the
risk of contamination and improved the overall safety and quality of
plasma-derived products. Techniques such as chromatography, ultrafiltration,
and cryoprecipitation are now being optimized to increase both the scale and
consistency of production.
The continuous development of more refined
fractionation technologies has improved the efficiency of production, making it
more affordable and sustainable. Companies in the plasma fractionation market
are also exploring novel techniques that focus on maximizing plasma yield while
minimizing costs, making plasma collection and processing more economically
viable. As these technologies advance, the market will continue to grow, driven
by the need to meet global demand for plasma-derived therapies.
Segmental Insights
Product Insights
Based on the product, Immunoglobulins are currently the fastest-growing segment in the global blood plasma fractionation market. Immunoglobulins, particularly intravenous immunoglobulin (IVIG), represent the largest and fastest-growing therapeutic class derived from blood plasma. Immunoglobulins are essential for treating a wide range of conditions, including primary immunodeficiencies (PID), autoimmune disorders, and infections. The growing prevalence of immunodeficiencies, autoimmune diseases, and increasing awareness of immunoglobulin therapy’s effectiveness have significantly boosted their demand in recent years.
The global increase in the number of patients diagnosed with autoimmune diseases, such as rheumatoid arthritis, lupus, and multiple sclerosis, has contributed to the expanding use of immunoglobulins. Immunoglobulins are often used in the treatment of rare diseases such as Guillain-Barré syndrome and chronic inflammatory demyelinating polyneuropathy (CIDP), further driving demand. IVIG is commonly used in hospitals and outpatient settings for patients who require long-term immune support due to compromised immune systems. As the aging global population is more susceptible to infections and immune-related disorders, the need for immunoglobulin therapies is expected to continue growing.
In addition to autoimmune diseases, the rise in infectious diseases has led to greater reliance on immunoglobulins for post-exposure prophylaxis and treatment. The ongoing COVID-19 pandemic highlighted the importance of immunoglobulin therapy, with convalescent plasma-based therapies being explored as treatments for viral infections, further boosting the demand for immunoglobulins. This surge in demand, combined with increased research into the therapeutic benefits of immunoglobulins in treating a broader spectrum of diseases, has reinforced the dominance of this segment in the blood plasma fractionation market..
End Use Insights
Based on the end use
segment, Hospitals & Clinics was the dominant segment. The demand for
plasma-derived products, such as immunoglobulins, albumin, coagulation factors,
and other therapeutics, is primarily driven by their widespread use in hospital
and clinic settings for the treatment of various diseases and medical
conditions. These healthcare facilities account for the largest share of the
market due to their role as the primary point of care for patients requiring
plasma-based therapies.
Hospitals are critical in providing urgent,
life-saving treatments for patients with chronic conditions like hemophilia,
immunodeficiencies, and autoimmune diseases, all of which rely heavily on
plasma-derived products. For example, intravenous immunoglobulin (IVIG) is
commonly administered in hospitals for patients with primary immunodeficiencies
and autoimmune disorders such as rheumatoid arthritis and lupus. Hospitals are
also the key settings for treating severe burns, liver diseases, and shock, where
albumin is often used as a vital treatment to restore blood volume and maintain
osmotic pressure.
In addition to routine treatments, hospitals and
clinics play a crucial role in the treatment of acute medical conditions. For
example, plasma-derived coagulation factors are frequently used in emergency
care settings to treat bleeding episodes in patients with hemophilia or other
clotting disorders. These facilities are equipped to handle the specialized
care and monitoring required for administering plasma-derived therapies,
further solidifying their dominance in the market. The large number of patients
in need of these treatments and the need for immediate intervention in clinical
settings ensure that hospitals and clinics remain the largest consumers of
plasma-derived products.
Download Free Sample Report
Regional Insights
North America was the dominant region in
the global blood plasma fractionation market. The United States, in particular,
plays a significant role in this dominance, contributing the largest share of
the market in terms of both plasma collection and consumption of plasma-derived
therapies. The robust healthcare infrastructure, advanced medical research
capabilities, and high demand for plasma-derived products like immunoglobulins,
albumin, and clotting factors have positioned North America as the leader in the
blood plasma fractionation market.
One of the key drivers of North America’s dominance
is the high prevalence of diseases that require plasma-based treatments, such
as hemophilia, autoimmune disorders, and immunodeficiencies. In the U.S., an
aging population and increased awareness of the effectiveness of plasma-derived
therapies contribute to the growing demand for these products. The rise in
chronic diseases, including rheumatoid arthritis, multiple sclerosis, and
primary immunodeficiencies, further fuels the need for plasma therapies in the
region. These treatments are primarily administered in hospitals and clinics,
which are abundant and well-equipped to handle the complex requirements of
plasma-derived therapies. This high demand for plasma products ensures that
North America remains the largest market for blood plasma fractionation.
The United States has a well-established and
expansive network of plasma collection centers, which ensures a steady supply
of plasma for fractionation. The country’s commitment to plasma donation
programs, supported by both public and private sectors, has helped create a
strong and reliable plasma supply chain. Plasma donation is encouraged through
compensation programs, which incentivize individuals to donate regularly,
thereby boosting the availability of raw plasma. The U.S. also leads in the
development and approval of new plasma-derived therapies, which further
strengthens its position in the global market.
Recent Developments
- In July 2024, Biotest AG revealed that it had laid
the foundation for an agreement with Kedrion to fully commercialize and
distribute its immunoglobulin product, Yimmugo, in the U.S., following the
FDA's approval of its Biologic License Application (BLA) for Yimmugo.
- In January 2024, Takeda announced that the FDA had
approved Immune Globulin Infusion 10% solution as an intravenous immunoglobulin
therapy, designed to improve neuromuscular disability and impairment in adults
suffering from chronic inflammatory demyelinating polyneuropathy.
- In August 2023, Shilpa Medicare Limited
successfully completed its Phase 1 clinical trial for recombinant human albumin
20%.
- In March 2023, in Germany, CSL celebrated
the opening of a new plasma fractionation facility, a USD 470 million project
that took five years to complete. The inauguration was attended by company
leaders and local officials in Marburg, a growing hub for biotech innovation.
Earlier in September, CSL also made a significant investment in research and
development in Marburg by unveiling a state-of-the-art research space for 500
employees. CSL Behring, a division of CSL, produces medicines for rare and
serious diseases using donated human plasma. The new fractionation facility,
equipped with modern technologies, optimized process flows, and automation,
significantly boosts production capacity, quadrupling the current output. The
fractionation process separates plasma into essential components like albumin,
immunoglobulin, and other proteins.
Key Market Players
- Grifols, S.A.
- CSL Limited
- Takeda Pharmaceutical Company
Limited
- Octapharma AG
- Kedrion S.p.A
- Biotest AG
- Bio Products Laboratory Ltd.
- Intas Pharmaceuticals Ltd.
- ADMA Biologics, Inc.
- Meiji Holdings Co., Ltd.
|
By Product
|
By Method
|
By Application
|
By End Use
|
By Region
|
- Albumin
- Immunoglobulins
- Coagulation
Factors
- Protease
Inhibitors
- Others
|
- Centrifugation
- Depth
Filtration
- Chromatography
- Others
|
- Neurology
- Haematology
- Oncology
- Immunology
- Pulmonology
- Others
|
- Hospitals
& Clinics
- Clinical
Research
- Others
|
- North
America
- Europe
- Asia Pacific
- South
America
- Middle East
& Africa
|
Report Scope:
In this report, the Global Blood Plasma
Fractionation Market has been segmented into the following categories, in
addition to the industry trends which have also been detailed below:
- Blood Plasma Fractionation Market, By Product:
o Albumin
o Immunoglobulins
o Coagulation Factors
o Protease Inhibitors
o Others
- Blood Plasma Fractionation Market, By Method:
o Centrifugation
o Depth Filtration
o Chromatography
o Others
- Blood Plasma Fractionation Market, By Application:
o Neurology
o Haematology
o Oncology
o Immunology
o Pulmonology
o Others
- Blood Plasma Fractionation Market, By End Use:
o Hospitals & Clinics
o Clinical Research
o Others
- Blood Plasma Fractionation Market, By Region:
o North America
§ United States
§ Canada
§ Mexico
o Europe
§ France
§ United Kingdom
§ Italy
§ Germany
§ Spain
o Asia-Pacific
§ China
§ India
§ Japan
§ Australia
§ South Korea
o South America
§ Brazil
§ Argentina
§ Colombia
o Middle East & Africa
§ South Africa
§ Saudi Arabia
§ UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Blood
Plasma Fractionation Market.
Available Customizations:
Global Blood Plasma Fractionation market report
with the given market data, TechSci Research offers customizations according to
a company's specific needs. The following customization options are available
for the report:
Company Information
- Detailed analysis and profiling of additional
market players (up to five).
Global Blood Plasma Fractionation Market is an
upcoming report to be released soon. If you wish an early delivery of this
report or want to confirm the date of release, please contact us at [email protected]